NRx Pharmaceuticals develops ketamine-based and other drugs for central nervous system disorders such as depression and PTSD. NRXP reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 1 | Ascendiant Capital | Maintained | Buy | |
| Aug 18 | BTIG | Reiterated | Buy | |
| Aug 7 | BTIG | Maintained | Buy |
Seasonality
How NRXP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
Whale Options Flow
90DNo whale options trades in NRXP in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NRXP is in one of them and how their past NRXP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NRXP in an article yet. Here's the latest on the wider market.
About NRX Pharmaceuticals
NRx Pharmaceuticals is a drug developer based in Wilmington, Delaware, focused on treatments for central nervous system disorders such as depression, post traumatic stress disorder, chronic pain and schizophrenia. Its lead product candidates are ketamine formulations, including a generic version called KETAFREE, and NRX-101, a combination of D-cycloserine and lurasidone, all still awaiting approval from the U.S. Food and Drug Administration. Through its majority owned subsidiary HOPE Therapeutics, the company also runs clinics in Florida that offer interventional psychiatry care to patients with treatment resistant depression and PTSD.
- Headquarters
- Wilmington, DE